share_log

Recursion Pharmaceuticals | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Gibson Christopher

Recursion Pharmaceuticals | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Gibson Christopher

Recursion Pharmaceuticals | 4/A：持股变动声明(修正)-高管 Gibson Christopher
美股sec公告 ·  07/12 18:58
Moomoo AI 已提取核心信息
Christopher Gibson, Chief Executive Officer of Recursion Pharmaceuticals, completed an acquisition of 100,000 shares of the company's Class A Common Stock on June 5, 2024. The transaction was carried out directly with no cost associated with the acquisition. Following this transaction, Gibson's total direct holdings in Recursion Pharmaceuticals amount to 908,738 shares. The transaction reflects a significant increase in the CEO's stake in the company, which could be indicative of his confidence in the firm's prospects.
Christopher Gibson, Chief Executive Officer of Recursion Pharmaceuticals, completed an acquisition of 100,000 shares of the company's Class A Common Stock on June 5, 2024. The transaction was carried out directly with no cost associated with the acquisition. Following this transaction, Gibson's total direct holdings in Recursion Pharmaceuticals amount to 908,738 shares. The transaction reflects a significant increase in the CEO's stake in the company, which could be indicative of his confidence in the firm's prospects.
Recursion药品的首席执行官Christopher Gibson在2024年6月5日以无成本直接获得方式收购了该公司100,000股A类普通股，此次交易使Gibson在Recursion药品的直接持股总数达到908,738股。这次交易反映出该公司的首席执行官对公司前景的信恳智能。
Recursion药品的首席执行官Christopher Gibson在2024年6月5日以无成本直接获得方式收购了该公司100,000股A类普通股，此次交易使Gibson在Recursion药品的直接持股总数达到908,738股。这次交易反映出该公司的首席执行官对公司前景的信恳智能。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息